Table 1. Clinicopathological features associated with NY-ESO-1 promoter methylation in stage 3 NSCLC patients.
| Variables | NY-ESO-1 Low Meth N = 14 n (%) | NY-ESO-1 High Meth N = 80 n (%) | P-value |
|---|---|---|---|
| Age, mean (range) years | 63.1 (46.2 – 85.6) | 64.4 (29.0 – 81.4) | 0.656 |
| Male | 9 (64) | 43 (54) | 0.566 |
| Smoker/Ex-Smoker | 14 (100) | 66 (83) | 0.119 |
| Histology Adenocarcinoma Squamous Other |
4 (29) 5 (36) 5 (36) |
47 (59) 22 (28) 11 (14) |
0.059 |
| Mutations TP53 KRAS EGFR PIK3CA MET |
2 (14) 2 (14) 0 (0) 1 (7) 0 (0) |
5 (6) 16 (20) 12 (15) 6 (8) 3 (4) |
0.291 0.616 0.121 0.963 0.462 |
| NY-ESO-1 IHC +ve IHC -ve |
11 (79) 3 (21) |
15 (19) 65 (81) |
< 0.0001 |
| Overall survival, mean (range) months All patients Adjuvant chemotherapy No chemotherapy |
14.8 (0.6 – 37.5) 22.2 (9.4 – 37.5) 9.3 (0.6 – 35) |
29.1 (0.03 – 146.5) 28.5 (0.60 – 117.1) 29.6 (0.03 – 146.5) |
0.003 0.149 0.004 |